White Paper: FDA's Shifting Goalposts—The Human and Economic Cost of Post Hoc Regulatory Rigidity in Biologics (2025–2026)

By Peter J. Pitts and Robert Goldberg

White Paper: FDA's Shifting Goalposts—The Human and Economic Cost of Post Hoc Regulatory Rigidity in Biologics (2025–2026)

Executive Summary

The regulatory landscape for biological products in the United States has undergone a fundamental transformation between April 2025 and February 2026. Under new leadership at the FDA and CBER, the agency has moved away from the "regulatory flexibility" that characterized the 2022–2024 era, opting instead for a posture of "radical transparency" and a strict adherence to randomized, controlled trials (RCTs) over surrogate endpoints and single-arm studies. This paper quantifies the impact of these delays—estimating billions in additional development costs and irreversible clinical decline for thousands of children—and demonstrates that many of today's standard-of-care gene therapies would have failed to achieve approval under the current regime.

1. The Post Hoc Standard: Reversing Precedent

Between 2022 and 2024, the FDA successfully utilized surrogate endpoints (e.g., micro-dystrophin, NfL) and single-arm trials to grant early access to breakthroughs in ALS, DMD, and oncology. However, correspondence from April 2025 to February 2026 reveals a systematic rejection of these same evidentiary markers.

Comparison of Regulatory Eras

Regulatory Feature	2022 – 2024 Standards	2025 – 2026 Post Hoc Standards
Pivotal Trial Design	Acceptance of single-arm studies (e.g., *Carvykti, Amtagvi*)	Mandate for randomized superiority trials (e.g., *Ebvallo, RP1*)
Endpoint Validity	Surrogate endpoints "reasonably likely to predict" (e.g., *Qalsody, Elevidys*)	Skepticism of biomarkers; requirement for functional clinical outcomes (e.g., *RGX-121*)
Confirmatory Timing	Confirmatory trials agreed upon post-approval	Confirmatory trials must be "underway and enrolling" prior to BLA review
Transparency	CRL details confidential between Agency and Sponsor	Real-time public disclosure of all deficiencies

2. The Economic Burden of Regulatory Volatility

The requirement for new, randomized trials in response to a Complete Response Letter (CRL) is the single most expensive regulatory event for a biotech firm.

Direct Remediation Costs

- **New Phase 3 Pivotal Trial:** Median costs for pivotal trials in biologics now range from $20 million to over $100 million per study.
- **Per-Patient Cost:** Clinical trials for new drugs cost a median of $41,117 per patient. In rare diseases where recruitment is globally distributed, these costs often double due to site management and travel.
- **Regulatory User Fees:** Resubmissions requiring new clinical data now cost $4,682,003 in application fees for FY 2026.

The "Time-is-Money" Delay Factor

A Class 2 resubmission typically incurs a median delay of 13 months, with clinical trial mandates extending that window to 2 to 3 years. For a pre-revenue biotech, this delay often triggers catastrophic market cap loss:

- **Average market reaction to CRL:** -4.34% within 3 days.
- **Severe reversals (e.g., Ebvallo):** Stock plunges of 57% and 90% headcount reductions.

3. The Human Cost: Depriving Access to Early Intervention

The most tragic consequence of shifting goalposts is the disconnect between **universal screening** and **treatment availability**. Diagnostics currently identify children at birth for diseases where treatments are now stalled in regulatory limbo.

The Diagnostic-Treatment Gap

Disease	Early Detection Method (Diagnostic)	Leading Manufacturer	Treatment Currently Delayed/Blocked
SMA	SMN1 real-time PCR (NBS)	Revvity, Labsystems	*Apitegromab* (CRL Sep 2025)
DMD	CK-MM enzyme assay (NBS)	Revvity, PerkinElmer	*Deramiocel* (CRL Jul 2025)
Hunter Syndrome	I2S activity fluorometric assay	Revvity, GelbChem	*RGX-121* (CRL Feb 2026)
EBV+ PTLD	qPCR for EBV DNAemia	Roche Diagnostics	*Ebvallo* (CRL Jan 2026)
Sanfilippo A (MPS IIIA	Genetic testing	ScreenPlus	*UX-111 (CRL Aug. 2025*

Mortality and Severity Projections During Delays

EBV+ PTLD Epstein-Barr Virus–positive Post-Transplant Lymphoproliferative Disorder. This is a serious and potentially life-threatening complication that can occur after an organ or stem cell transplant. It happens when the Epstein-Barr Virus (EBV), which many people carry without symptoms, causes uncontrolled growth of certain white blood cells

(lymphocytes) due to the immune system being suppressed by anti-rejection medications. For patients whose disease does not respond to the first line of treatment, the median overall survival (OS) is less than one month—highlighting the urgent need for effective therapies for this condition

Ebvallo (CRL Jan 2026) now faces a 13-month regulatory delay representing a 100% mortality rate for the cohort identified during that window.

Sanfilippo A (MPS IIIA): Sanfilippo Syndrome Type A, also known as Mucopolysaccharidosis Type IIIA (MPS IIIA), is a rare, inherited metabolic disorder that primarily affects the brain and nervous system. It is caused by a deficiency of the enzyme heparan N-sulfatase, which is needed to break down heparan sulfate, a complex sugar molecule. Without this enzyme, heparan sulfate accumulates in the cells, especially in the brain, leading to progressive neurological damage.

Children with Sanfilippo A typically experience developmental delays, behavioral issues, and gradual loss of cognitive abilities. Over time, they may lose skills such as speech and mobility, and their condition worsens as brain volume decreases—at a rate of about 2.7% per year, as noted in your document. This progressive brain atrophy results in severe intellectual disability and other neurological symptoms. The disease is life-limiting, with most affected children not surviving into adulthood.

The 13-month delay requested in the July 2025 CRL for UX111 results in irreversible gray matter loss.

4. Retroactive Failure Analysis

If the 2025–2026 standards (requiring functional primary endpoint success and randomized trials) were applied to products approved between 2022 and 2024, the impact would have been devastating:

- **Elevidys** (Approved 2023): Elevidys is a gene therapy developed for the treatment of Duchenne Muscular Dystrophy (DMD). It delivers a shortened, functional version of the dystrophin gene—called micro-dystrophin—into muscle cells using an adeno-associated virus (AAV) vector. The goal is to enable muscle cells to produce micro-dystrophin, which helps stabilize and protect muscle fibers that are otherwise damaged due to the lack of functional dystrophin in DMD patients. Although

  Elevidys failed its primary clinical endpoint (the North Star Ambulatory Assessment, or NSAA), it was approved based on the "totality of evidence" and the surrogate marker of increased micro-dystrophin expression in muscle tissue. Under the 2025

"primary endpoint primacy" rule that blocked *Lytenava*, **thousands of DMD children would currently have zero access** to gene therapy.

- **Qalsody** (Approved 2023): Qalsody is a therapy developed for the treatment of amyotrophic lateral sclerosis (ALS), specifically for patients with mutations in the SOD1 gene. ALS is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately respiratory failure.

  Qalsody was evaluated in the VALOR trial, where it failed to meet its primary efficacy endpoint—meaning the main clinical measure of benefit was not achieved. However, the drug was approved based on its ability to reduce neurofilament light chain (NfL) levels, a biomarker associated with neuronal injury. The approval relied on this surrogate marker, rather than direct clinical benefit.

  If the 2026 regulatory standard, which questions the validity of surrogate endpoints as seen with the RGX-121 precedent, had been applied, Qalsody would not have been approved, leaving patients without access to this therapy.

- **Amtagvi** & Casgevy (Approved 2023/24): Amtagvi and Casgevy are advanced cell therapies used for treating severe genetic blood disorders—such as sickle cell disease and beta thalassemia. These conditions are caused by mutations that affect the production or function of hemoglobin, resulting in chronic anemia, pain, and organ damage.

  Both therapies were approved based on data from single-arm, open-label clinical trials, meaning all participants received the therapy and there was no randomized control group. This approach is often used in rare diseases where recruiting enough patients for large, randomized trials is challenging.

  However, under the 2026 "Ebvallo Reversal," which mandates randomized superiority trials for cell therapies, these products would still be awaiting approval in Phase 3 trials. This illustrates how stricter regulatory requirements can delay access to potentially life-saving treatments for patients with rare and serious diseases.

5. The Collision of Policy: HHS Screening Expansion vs. Regulatory Stagnation

A profound internal contradiction has emerged within the current administration's health policy. On December 16, 2025, Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. significantly expanded the federal Recommended Uniform Screening Panel (RUSP) by adding Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD). This directive was intended to ensure that children with these devastating disorders are identified at birth to maximize the benefits of early intervention.

However, the "goalpost movement" within CBER effectively nullifies these gains. While Secretary Kennedy's expansion identifies DMD infants earlier than ever, the FDA's new insistence on randomized trials for cell therapies and its skepticism of surrogate markers have stalled approval for critical therapies like **deramiocel (CAP-1002)** for DMD cardiomyopathy. This creates a "cruel paradox" of diagnosis without therapy: a child identified via federal screening panels will receive a definitive diagnosis only to be told that the necessary treatment is frozen in a 3-year regulatory delay to satisfy new randomized trial mandates. The efficacy of therapies for MLD and DMD depends entirely on pre-symptomatic treatment, yet the CBER policy shifts actively obstruct the window of opportunity that federal screening creates.

6. "Rigged to Fail": The Paradox of Randomization in Micro-Populations

The recent shift by CBER leadership toward mandating randomized controlled trials (RCTs) for ultra-rare and highly heterogeneous populations is increasingly viewed by statisticians and clinical experts as a design paradigm "rigged to fail." While randomization is the "gold standard" for common conditions, its application to micro-populations creates a mathematical and ethical gauntlet that frequently leads to the rejection of effective therapies—a phenomenon known as a Type II Error (false negative).

The Type II Error Trap: Favoring "No Effect" by Design

In drug development for common diseases, regulators primarily guard against Type I errors (approving a drug that doesn't work). However, in ultra-rare diseases, the sample sizes are often so small (e.g., $N < 30$) that a trial lacks the statistical power to reach the traditional $p < 0.05$ threshold unless the treatment effect is near-miraculous.

- **The Power Deficit:** Achieving sufficient statistical power typically requires large patient volumes. In rare diseases, standard RCTs are often underpowered by default, making them statistically predisposed to fail to reject the null hypothesis, even if the drug is clinically beneficial.

- **False Negatives as the Primary Risk:** For patients with fatal conditions like EBV+ PTLD or Sanfilippo A, a Type II error (denying a working drug) is far more devastating than a Type I error (approving an ineffective one), as the "null hypothesis" for these patients is rapid decline or death.

The Heterogeneity Conflict: Noise Drowning Out the Signal

Ultra-rare populations are not only small but characterized by extreme Treatment Effect Heterogeneity (TEH). Patients vary wildly in age of onset, genetic mutation type, and baseline disease severity.

- **The Failure of Randomization in Micro-Cohorts:** The primary goal of randomization is to balance prognostic factors between groups. In a trial of 20 patients, randomization can easily result in "imbalanced arms" by pure chance. One arm may inadvertently contain "rapid progressors," while the other contains "slow progressors," creating enough "noise" to drown out any evidence of clinical benefit.
- **Subgroup Invisibility:** Because the total population is so small, underpowered subgroup analyses cannot reliably identify who is responding to the drug, leading to a "one-size-fits-all" failure for a precision medicine product.

"Rigged to Fail": The Mathematical Impossibility of Success

Statisticians argue that requiring randomized superiority trials for these populations is essentially a regulatory dead end:

- **The Infeasibility of Recruitment:** 33% of discontinued rare disease trials fail solely due to insufficient patient accrual. Mandating a control arm effectively doubles the number of patients needed, which is often logistically impossible for diseases affecting fewer than 1,000 people globally.
- **Confounding Interpretation:** In the 2026 rejection of **Ebvallo (tabelecleucel)**, the FDA claimed that the single-arm trial design "confounded" the results, despite having previously aligned on that very design for years. This "post hoc" pivot ignores that in many ultra-rare settings, there is no "standard of care" to use as a randomized comparator, forcing sponsors to use a placebo arm that many patients will refuse to join for ethical reasons.

Ethical Malfeasance: The "Window of Opportunity"

For progressive neurodegenerative diseases, every month spent in a randomized, placebo-controlled trial represents a permanent loss of function.

- **Irreversible Decline:** In Hunter syndrome (RGX-121) and Sanfilippo A (UX111), children lose significant brain volume (up to 2.7% annually) while waiting for approval. Forcing a 2-to-3-year randomized trial means that by the time the data is collected, the children in the control arm may have progressed past the point where the therapy can help.
- **Mortality in the Control Arm:** In aggressive malignancies like EBV+ PTLD, where median survival after rituximab failure is only 0.7 months, a randomized trial is a death sentence for the control group.

A Design Without a Purpose

Critically, the move toward randomization in 2025–2026 appears to prioritize institutional "purity" over clinical reality. By mandating a design that is statistically destined to produce "inconclusive" results in small, varied populations, the agency is effectively closing the door on the most vulnerable patient communities. Experts suggest that instead of "rigged" RCTs, the agency should lean into **Target Trial Emulation (TTE)** and **Causal Machine Learning**, which use synthetic controls to establish treatment effects without the human or mathematical costs of traditional randomization.

7. Conclusion: A Call for Consistency

The data indicates that the "black-box" of the past has been replaced by a "shifting fence" in the present. While clinical rigor is essential, applying new standards post hoc to drugs already years into the review cycle destroys the "predictability" that both capital markets and patient communities require. By abandoning the pathways that enabled the first wave of gene therapies, the Agency risks a "lost generation" of children who were identified through the miracle of early screening but left with no treatment due to regulatory volatility.

Methodology and Data Analysis

This report was generated using a multi-phase analytical framework to synthesize regulatory actions, clinical endpoints, and socioeconomic impacts.

Data Collection and Sources

Primary data on Biologics License Application (BLA) outcomes and Complete Response Letters (CRLs) were derived from the openFDA transparency database, which provided real-time access to unapproved application deficiencies between April 2025 and February 2026. This was supplemented by CBER noteworthy approval registries and PDUFA goal date tracking from industry archives. Strategic policy shifts were identified via a review of CBER leadership's perspective pieces in journals such as JAMA and NEJM, as well as formal FDA guidance documents issued during the study period.

Quantitative and Qualitative Analysis

Economic impact modeling utilized standard industry benchmarks for Phase 3 pivotal trial costs ($20 million to $100+ million) and remediation expenses associated with FDA 483 observations ($250,000 to $5 million). Time-to-resolution metrics were based on historical RAPS and Datamonitor analysis, identifying a median delay of 13 months for Class 2 major resubmissions.

Human health impacts were estimated by synthesizing longitudinal natural history data for ultra-rare neurodegenerative and oncological indications (e.g., annual 2.7% brain volume loss in Sanfilippo A and 0.7-month median OS in rituximab-refractory PTLD). Statistical validity was critically assessed through the lens of Causal Machine Learning (CML), focusing on Target Trial Emulation (TTE) and Targeted Maximum Likelihood Estimation (TMLE) to evaluate the feasibility of randomization in heterogeneous micro-populations.

References

1. BioSpace. "2025 Reshaped the FDA. What Will 2026 Hold?" (January 2026).
2. Pink Sheet. "Accelerated Approvals Perked Up While US FDA Excelled At Being Average In 2025" (January 2026).
3. Pink Sheet. "US FDA Holds Steady With 58 Novel Approvals In 2025 Despite Upheaval" (January 2026).

4. openFDA. "Complete Response Letters Database" (Current as of February 2026).
5. Arnold & Porter. "FDA Plausible Mechanism Pathway and Other Initiatives for Ultra-Rare Conditions" (November 2025).
6. Arnold & Porter. "Transparency So Radical It Overlooks Law: FDA Releases CRLs for Unapproved Drugs" (September 2025).
7. Latham & Watkins. "FDA Publishes Complete Response Letters for Unapproved Drug Applications" (September 2025).
8. FDA Guidance. "Patient-Focused Drug Development: Selecting Fit-for-Purpose Clinical Outcome Assessments" (October 2025).
9. Optometry Times. "FDA sends CRL to Outlook Therapeutics for ONS-5010 Resubmission" (December 2025).
10. Outlook Therapeutics. "Press Release: Norse Eight Primary Endpoint Results" (December 2025).
11. Outlook Therapeutics. "Type A Meeting Request to FDA Following CRL" (February 2026).
12. Atara Biotherapeutics. "Regulatory and Business Update on EBVALLO (tabelecleucel)" (January 2026).
13. Targeted Oncology. "For a Second Time, FDA Denies Approval of Tab-Cel in EBV+ PTLD" (January 2026).
14. Atara Biotherapeutics. "Reversal of Position by FDA on Single Arm ALLELE Trial" (January 2026).
15. Replimune. "Replimune Announces Complete Response Letter from FDA for RP1" (July 2025).
16. REGENXBIO. "Regulatory Update on RGX-121 BLA for MPS II" (February 2026).
17. Contemporary Pediatrics. "FDA issues CRL for RGX-121 Gene Therapy in Hunter Syndrome" (February 2026).
18. PRNewswire. "REGENXBIO RGX-121 BLA Support and Campsite Trial Data" (February 2026).
19. CGTlive. "Ultragenyx resubmits BLA for MPS IIIA Gene Therapy UX111" (February 2026).

20. Ultragenyx. "Resolvable Facility and Process Related CMC Issues in UX111 CRL" (July 2025).
21. BioSpace. "Ultragenyx Gene Therapy Shows Long-Term Cognitive Improvements in Sanfilippo" (February 2026).
22. SEC. "Ultragenyx Pharmaceutical BLA Resubmission and CMC Response" (January 2026).
23. Drugs.com. "Development Timeline and Approval for Zycubo (Copper Histidinate)" (January 2026).
24. Nasdaq. "Weekly Buzz: FDA Refuses to Accept MOLBREEVI BLA" (March 2025).
25. Pink Sheet. "US FDA Rejection Reveals New Barriers for Sanofi's Tolebrutinib" (January 2026).
26. NeurologyLive. "FDA Accepts Regulatory Submission for BTK Inhibitor Tolebrutinib" (March 2025).
27. Scholar Rock. "FDA Issues Complete Response Letter (CRL) for Apitegromab" (September 2025).
28. Capricor Therapeutics. "Anti-Fibrotic Activity and Potency Assay for Deramiocel" (November 2025).
29. Capricor Therapeutics. "Capricor and FDA Align on Path to Potential Approval Following CRL" (September 2025).
30. Pharmacy Times. "FDA Declines to Review Moderna’s mRNA-1010 Flu Vaccine Application" (February 2026).
31. PharmExec. "FDA Sends Refusal-to-File Letter to Moderna Over Comparator Concerns" (February 2026).
32. Moderna. "Moderna Statement on RTF Letter for mRNA-1010 Seasonal Flu Vaccine" (February 2026).
33. FDA. "Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure" (2025 Update).
34. Oh J, et al. "Paramagnetic Rim Lesions as a Prognostic Biomarker in Multiple Sclerosis" (2025).
35. FDA. "Approved Cellular and Gene Therapy Products" (Current as of December 2025).

36. ResearchGate. "A Prospective Natural History Study of Mucopolysaccharidosis IIIA and IIIB" (2024).

37. HHS. "Secretary Kennedy Adds Duchenne Muscular Dystrophy to Newborn Screening Panel" (December 2025).

38. Sofpromed. "Ultimate Guide: Clinical Trial Costs in the United States" (2025).

39. Inotek. "Dollar Cost of QA/QC Failures and FDA 483 Observations" (January 2026).

40. FDA. "Prescription Drug User Fee Rates for Fiscal Year 2026" (July 2025).

41. SSRN. "Stock Market Reactions to FDA Complete Response Letter Disclosures" (January 2026).

42. FDA. "New Drug Therapy 2024 Annual Report: Innovation and Approvals" (January 2025).

43. FDA. "Elevidys Accelerated Approval Clinical Review Memo" (June 2023).

44. Mohty M, et al. "Outcomes for EBV+ PTLD Following HCT Who Fail Rituximab" (2024).

45. ThinkFA. "Friedreich Ataxia Progression and mFARS Annual Change Rate" (2024).

46. ERSnet. "Cardiomyopathy Mortality and LVEF Decline Rate in Duchenne Muscular Dystrophy" (2023).

Works cited

1. Complete Response Letters (CRLs) - openFDA, https://open.fda.gov/apis/transparency/completeresponseletters

2. FDA Policy Tracker: 2025 Was a Year of Change - BioSpace, https://www.biospace.com/fda/fda-policy-tracker-2025-was-a-year-of-change

3. Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel), https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business

4. FDA Slams REGENXBIO's MPS II Gene Therapy RGX-121 With CRL | CGTlive®, https://www.cgtlive.com/view/fda-slams-regenxbio-mps-ii-gene-therapy-rgx-121-crl

5. Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to US FDA, https://ir.ultragenyx.com/news-

releases/news-release-details/ultragenyx-resubmits-biologics-license-application-ux111-aav

6. Ultragenyx's Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies, https://www.biospace.com/drug-development/ultragenyxs-gene-therapy-shows-long-term-efficacy-in-two-sanfilippo-studies

7. Outlook Therapeutics requests FDA Type A meeting after CRL | OTLK Stock News, https://www.stocktitan.net/news/OTLK/outlook-therapeutics-submits-type-a-meeting-request-to-fda-following-d8vq6wlinhrp.html

8. FDA issues CRL for RGX-121 gene therapy in ..., https://www.contemporarypediatrics.com/view/fda-issues-crl-for-rgx-121-gene-therapy-in-mucopolysaccharidosis-type-ii

9. FDA Action Update, November 2025: Approvals, Clearance, and Boxed Warning, https://www.neurologylive.com/view/fda-action-update-november-2025-approvals-clearance-boxed-warning

10. FDA Action Update, January 2026: Approvals, Acceptance, and Clearance, https://www.neurologylive.com/view/fda-action-update-january-2026-approvals-acceptance-and-clearance

11. For a Second Time, FDA Denies Approval of Tab-Cel in EBV+ PTLD | Targeted Oncology, https://www.targetedonc.com/view/for-a-second-time-fda-denies-approval-of-tab-cel-in-ebv-ptld

12. 2025 Biological License Application Supplement Noteworthy Approvals - FDA, https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2025-biological-license-application-supplement-noteworthy-approvals

13. CBER 2025 Orphan Approvals (new BLAs) - FDA, https://www.fda.gov/vaccines-blood-biologics/cber-2025-orphan-approvals-new-blas

14. 2025 Biological Approvals | FDA, https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2025-biological-approvals